BIO-TECHNE Corp (TECH)
BIO-TECHNE Corp (TECH) from its SEC filings: 2026 revenue $1.2 billion (-0% vs the year before), free cash flow $263.2 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2026) | $1.2 billion |
| Revenue growth | -0% |
| Free cash flow | $263.2 million |
| Diluted EPS | $1.16 |
| Latest quarter (Q1 2026 (calendar)) revenue vs a year earlier | -2% |
| Cash | $264.7 million |
| Share count, 1 year | +1% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.